Investment Banking

Investment Banking 2023-02-14T16:53:00+00:00

Seeing all sides, and knowing what matters.

Sectors of Focus

10 b - Investment Banking
M&A Transactions
25 m - Investment Banking
TRANSACTION SIZE
continents - Investment Banking
CONTINENTS

Seeing all sides, and knowing what matters.

Sectors of Focus

icon pharma - Investment Banking
PHARMACEUTICALS
icon services - Investment Banking
PHARMACEUTICAL SERVICES
icon health - Investment Banking
CONSUMER HEALTH & OTC

Typical Transaction

  • Sell-side M&A
  • Capital raising

EXPERIENCE + UNDERSTANDING

The Bourne Partners investment banking team understands opportunities from every angle and we concentrate on what’s important to you.

block-clincierge-greenphire-tb

Clincierge reduces the emotional, logistical, and financial barriers to clinical trial participation, enabling patients to access life-changing and potentially lifesaving new treatment options. Their high-touch patient concierge services include but are not limited to, individualized air and rail ticketing, hotel and housing accommodations, payment and reimbursement processes, and ongoing patient, family, and caregiver support. Their services reduce the emotional and financial stressors related to travel and out-of-pocket expenses related to clinical trial participation. They address unique patient and caregiver needs, and the many demands complex trial designs place on participants and their families, building custom solutions to specific study-related problems.

SECTOR: Pharmaceuticals
YEAR: January 2024
DEAL SIZE: Undisclosed
MANDATE TYPE: Sell-Side M&A Advisory

block-afton-acp

Afton Scientific is a contract, development and manufacturing organization (“CDMO”) that specializes in small-batch filling of injectables from clinical trials to approved commercial drugs. Afton has provided reliable pharmaceutical services and lasting relationships within the industry for over 30 years. Utilizing 35,000 square feet of manufacturing, lab, warehouse, and administrative space, Afton provides custom, innovative solutions for clinical to commercial sterile manufacturing, packaging and labeling, analytical and micro lab services, and pharmaceutical support services.

SECTOR: Pharmaceuticals
YEAR: January 2024
DEAL SIZE: Undisclosed
MANDATE TYPE: Sell-Side M&A Advisory

block-summit-kindeva

Summit Biosciences is a specialized pharmaceutical company focused on developing, manufacturing and commercializing generic and innovative nasal spray medicines. Summit collaborates on the development of products with their clients and manufactures at commercial scale for the US and European markets.

SECTOR: Pharmaceuticals
YEAR: January 2024
DEAL SIZE: Undisclosed
MANDATE TYPE: Sell-Side M&A Advisory

block-contipi-indegene

ConTIPI Medical Ltd provides non-surgical and disposable vaginal solutions for women with various Pelvic Floor Disorders (PFDs). ConTIPI’s first device for stress urinary incontinence (SUI), the Impressa device, was acquired by Kimberly Clark Worldwide and is available for sale. ConTIPI’s following innovation is the ProVate Device, intended to manage Pelvic Organ Prolapse (POP) in women.

SECTOR: Medical Device; Tech-Enabled Services
YEAR: May 2023
DEAL SIZE: Undisclosed
MANDATE TYPE: Commercialization

block-contipi-capIP-GTP

ConTIPI Medical Ltd provides non-surgical and disposable vaginal solutions for women with various Pelvic Floor Disorders (PFDs). ConTIPI’s first device for stress urinary incontinence (SUI), the Impressa device, was acquired by Kimberly Clark Worldwide and is available for sale. ConTIPI’s following innovation is the ProVate Device, intended to manage Pelvic Organ Prolapse (POP) in women.

SECTOR: Medical Device
YEAR: May 2023
DEAL SIZE: $40,000,000
MANDATE TYPE: Capital Raise

block-uphealth-medquest

UpHealth is a global digital health company that delivers digital-first technology, infrastructure, and services to dramatically improve how healthcare is delivered and managed. Innovations Group (“IGI”) is a group of companies / business units focused on providing integrative medicine and preventative health solutions for patients and prescribers through its 503A compounding pharmacy, CME accredited training and education platform, clinical grade supplements line, and analytical testing support services.

SECTOR: Pharmacy Services
YEAR: February 2023
DEAL SIZE: $56,000,000
MANDATE TYPE: Sell-Side Advisory

block-tapemark-LTS

Founded in 1952, Tapemark’s first service offering was printing on self-wound tape. As an early leader in pressure-sensitive adhesives, their expertise evolved to include single-use medical and personal care products. Today, Tapemark specializes in the development and manufacturing of multiple drug delivery systems delivering both Rx and OTC pharmaceuticals via transdermal patches, oral films, and unit dose topical applicators.

SECTOR: Pharmaceuticals
YEAR: August 2022
DEAL SIZE: Undisclosed
MANDATE TYPE: Sell-Side M&A Advisory

block-oakrum-ani

Oakrum Pharma, LLC is a privately-owned biopharmaceutical company focusing on development and commercialization of affordable drug therapies, located in St. Louis, Missouri. Through a business model of collaborating with experts in various disciplines and leveraging a global network of business partners, Oakrum Pharma intends to provide more options to small, specialty and rare disease markets.

SECTOR: Pharmaceuticals
YEAR: July 2022
DEAL SIZE: Undisclosed
MANDATE TYPE: Sell-Side M&A Advisory

block-fagron-signet

Fagron is a global, vertically integrated pharmaceutical company delivering personalized medical solutions safely to over 300,000 patient-focused customers. Fagron focuses on optimizing and innovating pharmaceutical compounding to widen the therapeutic scope of prescribers worldwide.

SECTOR: Pharmaceuticals
YEAR: February 2022
DEAL SIZE: Up to $10,000,000
MANDATE TYPE: Sell-Side Advisory

block-woodward-colbeck

Woodward Pharma Services LLC is a specialty pharmaceutical company focused on acquiring, licensing, and commercializing branded and generic prescription drugs for the U.S. market.  Woodward Pharma provides outsourced marketing, sales, and commercial services for the US pharmaceutical industry.

SECTOR: Specialty Pharma
YEAR: July 2021
DEAL SIZE: $125,000,000
MANDATE TYPE: Capital Raise

block-nuvera-udg

Nuvera Life Science is a consulting company dedicated to helping its clients design, build and manage a seamless patient and HCP treatment experience for rare disease and specialty therapeutics.

SECTOR: Pharma Services
YEAR: May 2021
DEAL SIZE: Up to $36 million
MANDATE TYPE: Company Sell-side

block-ani-novitium

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals.

SECTOR: Generic Pharma
YEAR: March 2021
DEAL SIZE: up to $249,000,000
MANDATE TYPE: Company Buy-side

CONNECTION + COLLABORATION

We collaborate with industry stakeholders and draw on strong relationships on both the advisory and strategic capital sides.

And we don’t stop until the deal is done.